Neurology Market: A BCC Research Overview

Report Highlights

The global market for neurology should grow from $33.3 billion in 2019 to $39.4 billion by 2024 at a compound annual growth rate (CAGR) of 3.5% for the period of 2019-2024.

Report Includes

• 15 data tables and 22 additional tables
• An in-depth overview and industry analysis of the global market for neurology medicines
• Analyses of the global market trends, with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024
• Historical background on neurological disorders and therapeutics, growing prevalence of neurological disorders, increasing research and development activities regarding neurology research, and analysis of the factors influencing the market
• Quantitative analysis of the neurology therapeutics market covering Parkinson Diseases, Alzheimer Diseases, Psychotic Disorders, Epileptic Disorders, Autism Disorders, and Brain Tumor Diseases
• Discussion of various therapeutics used for treatment of different neurological disorders, along with coverage of novel pipeline, patent expiry of blockbuster drug and new drug approvals
• Reviews of the competitive landscape, key strategies adopted by market players, mergers and acquisitions details, pipeline analysis covering ongoing clinical trials and promising forthcoming neuroscience therapies in late stage etc.
• Details company profile of leading participants within the neurology market including, AbbVie, Biogen, GlaxoSmithKline Plc, Johnson & Johnson, and Sun Pharmaceuticals Industries Ltd.

Report Scope

The scope of this report is broad and covers therapeutics used in treatment of neurological disorders.

The report highlights the current and future market potential of neurology medicines and provides a detailed analysis of the competitive environment, regulations, epidemiology of neurological diseases, merger and acquisition, drivers, restraints, and pipeline drugs in the market. The report also covers market projections through 2024.

The report details market shares of neurology based on different disease indication. Based on neurological disorders the market is segmented into Parkinson Diseases, Alzheimer Diseases, Psychotic Disorders, Epileptic Disorders, Autism Disorders, and Brain Tumor Diseases. Each diseases segment covers therapeutics and regional analysis.

The market of Parkinson Diseases covers anti-Parkinson’s drugs. The market is segmented into drug class and region. Based on drug class the market is segmented into dopaminergic, enzyme inhibitors, dopamine agonists and other Anti-Parkinson’s medications. Based on region the market is segmented into North America, Europe, Asia-Pacific, South America and Middle East and Africa.

The market of Alzheimer Diseases covers anti-Alzheimer drugs. the market is segmented based on mechanism of action of drugs and region. based on drug class the market is segmented into AChE inhibitors and NMDA antagonist. Based on region the market is segmented into North America, Europe, and Rest of the World.

The market of psychotic diseases covers antipsychotic drugs. The market is segmented into drug class and region. Based on drug, the market is segmented into D2 antagonists, D2/5HT2A antagonists, and D2 partial agonist. Based on region the market is segmented into North America, Europe, Asia-Pacific, South America and Middle East and Africa.

The market of Epileptic Diseases covers Anti-Epileptic Drugs. The market is segmented into drug class and region. Based on drug class the market is segmented into first generation drugs, second generation drugs, and third generation drugs. Based on region the market is segmented into North America, Europe, Asia-Pacific, South America and Middle East and Africa.

The market of autism disorder covers autism disorder therapeutics. The market is segmented into drug based on labelled information and region. Based on drug class the market is segmented into ASD-labeled pharmaceuticals and Off-label pharmaceuticals. Based on region the market is segmented into North America, Europe, and Rest of the World.

The market of brain tumor covers brain tumor therapeutics. The market is segmented into therapy type and region. Based on therapy type, the market is segmented into chemotherapy and targeted therapy. Based on region, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World.

For market estimates, data is provided for 2018 as the base year, with forecasts for 2019 through 2024. Estimated values are based on drug manufacturers’ total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

Analyst Credentials

BCC Publishing Staff comprises expert analysts who are skilled in conducting primary research, secondary research and data analysis and have decades of combined experience covering a wide range of industries, including healthcare, advanced materials and emerging technologies. Collectively, the team represents a diverse set of educational achievements with individual graduate work completed in fields such as microbiology, electrical engineering, business administration and surgery, among others.